|
1
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mehlen P and Puisieux A: Metastasis: A
question of life or death. Nat Rev Cancer. 6:449–458. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tiwari N, Gheldof A, Tatari M and
Christofori G: EMT as the ultimate survival mechanism of cancer
cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thiery JP, Acloque H, Huang RYJ and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liao JK: Clinical implications for statin
pleiotropy. Curr Opin Lipidol. 16:624–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gazzerro P, Proto MC, Gangemi G, Malfitano
AM, Ciaglia E, Pisanti S, Santoro A, Laezza C and Bifulco M:
Pharmacological actions of statins: A critical appraisal in the
management of cancer. Pharmacol Rev. 64:102–146. 2012. View Article : Google Scholar
|
|
8
|
Demierre MF, Higgins PD, Gruber SB, Hawk E
and Lippman SM: Statins and cancer prevention. Nat Rev Cancer.
5:930–942. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Menter DG, Ramsauer VP, Harirforoosh S,
Chakraborty K, Yang P, Hsi L, Newman RA and Krishnan K:
Differential effects of pravastatin and simvastatin on the growth
of tumor cells from different organ sites. PLoS One. 6:e288132011.
View Article : Google Scholar
|
|
10
|
Rao S, Porter DC, Chen X, Herliczek T,
Lowe M and Keyomarsi K: Lovastatin-mediated G1 arrest is
through inhibition of the proteasome, independent of hydroxymethyl
glutaryl-CoA reductase. Proc Natl Acad Sci USA. 96:7797–7802. 1999.
View Article : Google Scholar
|
|
11
|
Liu Y, Tang W, Wang J, Xie L, Li T, He Y,
Deng Y, Peng Q, Li S and Qin X: Association between statin use and
colorectal cancer risk: A meta-analysis of 42 studies. Cancer
Causes Control. 25:237–249. 2014. View Article : Google Scholar
|
|
12
|
Khurana V, Bejjanki HR, Caldito G and
Owens MW: Statins reduce the risk of lung cancer in humans: A large
case-control study of US veterans. Chest. 131:1282–1288. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi M, Zheng H, Nie B, Gong W and Cui X:
Statin use and risk of liver cancer: An update meta-analysis. BMJ
Open. 4:e0053992014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lustman A, Nakar S, Cohen AD and Vinker S:
Statin use and incident prostate cancer risk: Does the statin brand
matter? A population-based cohort study. Prostate Cancer Prostatic
Dis. 17:6–9. 2014. View Article : Google Scholar
|
|
15
|
Nielsen SF, Nordestgaard BG and Bojesen
SE: Statin use and reduced cancer-related mortality. N Engl J Med.
367:1792–1802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baker DL, Pham TC and Sparks MA: Structure
and catalytic function of sphingosine kinases: Analysis by
site-directed mutagenesis and enzyme kinetics. Biochim Biophys
Acta. 1831:139–146. 2013. View Article : Google Scholar
|
|
17
|
Kono Y, Nishiuma T, Nishimura Y, Kotani Y,
Okada T, Nakamura S and Yokoyama M: Sphingosine kinase 1 regulates
differentiation of human and mouse lung fibroblasts mediated by
TGF-beta1. Am J Respir Cell Mol Biol. 37:395–404. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Milara J, Navarro R, Juan G, Peiró T,
Serrano A, Ramón M, Morcillo E and Cortijo J:
Sphingosine-1-phosphate is increased in patients with idiopathic
pulmonary fibrosis and mediates epithelial to mesenchymal
transition. Thorax. 67:147–156. 2012. View Article : Google Scholar
|
|
19
|
Ai J, Tang Q, Wu Y, Xu Y, Feng T, Zhou R,
Chen Y, Gao X, Zhu Q, Yue X, et al: The role of polymeric
immunoglobulin receptor in inflammation-induced tumor metastasis of
human hepatocellular carcinoma. J Natl Cancer Inst. 103:1696–1712.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Haynes J, Srivastava J, Madson N, Wittmann
T and Barber DL: Dynamic actin remodeling during
epithelial-mesenchymal transition depends on increased moesin
expression. Mol Biol Cell. 22:4750–4764. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wendt MK, Allington TM and Schiemann WP:
Mechanisms of the epithelial-mesenchymal transition by TGF-beta.
Future Oncol. 5:1145–1168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu M, Bardia A, Wittner BS, Stott SL, Smas
ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, et al:
Circulating breast tumor cells exhibit dynamic changes in
epithelial and mesenchymal composition. Science. 339:580–584. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miraglia E, Högberg J and Stenius U:
Statins exhibit anticancer effects through modifications of the
pAkt signaling pathway. Int J Oncol. 40:867–875. 2012.
|
|
24
|
Argast GM, Krueger JS, Thomson S,
Sujka-Kwok I, Carey K, Silva S, O'Connor M, Mercado P, Mulford IJ,
Young GD, et al: Inducible expression of TGFβ, Snail and Zeb1
recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp
Metastasis. 28:593–614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alves CC, Carneiro F, Hoefler H and Becker
KF: Role of the epithelial-mesenchymal transition regulator Slug in
primary human cancers. Front Biosci. 14:3035–3050. 2009. View Article : Google Scholar
|
|
26
|
Shida D, Takabe K, Kapitonov D, Milstien S
and Spiegel S: Targeting SphK1 as a new strategy against cancer.
Curr Drug Targets. 9:662–673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xin C, Ren S, Kleuser B, Shabahang S,
Eberhardt W, Radeke H, Schäfer-Korting M, Pfeilschifter J and
Huwiler A: Sphingosine 1-phosphate cross-activates the Smad
signaling cascade and mimics transforming growth
factor-beta-induced cell responses. J Biol Chem. 279:35255–35262.
2004. View Article : Google Scholar : PubMed/NCBI
|
